Cited by 1273D Printing in Biomedical ResearchMicrofluidic and Capillary Electrophoresis ApplicationsCancer Cells and Metastasis

Cancer-on-a-chip systems at the frontier of nanomedicine

Open access
Zhang, Yu Shrike, Zhang, Yi-Nan, Zhang, Weijia·2017·Drug Discovery Today

Abstract

Nanomedicine provides a unique opportunity for promoting drug efficacy through enhanced delivery mechanisms. However, its translation into the clinics has been relatively slow compared with the large amount of research occurring in laboratory settings. Given the limitations of conventional cell culture models and preclinical animal models, we discuss the potential utility of recently developed cancer-on-a-chip platforms, which maximally replicate the pathophysiology of the human tumor microenvironments, as alternatives for effective evaluation of nanomedicine. We begin with a brief discussion of nanomedicine, then chart the history of organ-on-a-chip platform development and their recent evolution as tools for modeling different cancers for assessing nanomedicine efficacy, concluding with future perspectives for the field.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.drudis.2017.03.011

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Today, tumor-on-chip systems are the most promising embodiment of in vitro platforms capable of faithfully recapitulating relevant aspects of the biochemical complexity and dynamics of the tumor niche in a controlled environment with much lower variability than in vivo systems.

    “Today, tumor-on-chip systems are the most promising embodiment of in vitro platforms capable of faithfully recapitulation of relevant aspects of the biochemical complexity and dynamics of the tumor niche in a controlled environment (i.e., with much lower variability than is associated with in vivo systems [8,54,113]).”

    From The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors (2019) · cites this paper as [113]

    In “Modeling cancer biology and physiology in vitro” (page unavailable), the paper says cancer-on-a-chip systems can partially reproduce the complex, dynamic tumor microenvironment. “Cancer-on-a-chip platforms for evaluating nanomedicine” describes their close mimicry of in vivo biology, but the copy does not establish that they are the most promising in vitro platform or that they have much lower variability than in vivo systems. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Patient-on-chip platforms with engineered in vitro tissue models and patient-derived cells have the potential to revolutionize drug discovery and bring personalized medicine closer to reality.

    “Patient-on-chip platforms including engineered in vitro tissue models associated with patient derived cells (i.e. individual- and disease-specific hiPSCs) have the potential to revolutionize the drug discovery paradigm, and bring us closer towards the reality of personalized medicine [160,359,412].”
  • Microfluidic systems can link different organs-on-a-chip to potentially simulate the complexity of multiorgan drug metabolism and pharmacokinetics.

    “Furthermore, microfluidic systems can link different organs-on-a-chip to potentially simulate the complexity of multiorgan drug metabolism and pharmacokinetics9,47,50,68–71.”
  • Organ-on-a-chip devices possess good performance and improved recapitulation of the native microenvironment, and they allow high-throughput tests with decreased cost, ethical advantages and enhanced reproducibility.

    “Organ-on-a-chip devices possess good performance and improved recapitulation of the native microenvironment, and they allow high‐throughput tests with decreased cost, ethical advantages and enhanced reproducibility47,55–57.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Zhang, Y. S., Zhang, Y.-N., & Zhang, W.
Affiliations
  • Brigham and Women's Hospital (US)
  • Fudan University (CN)
Corresponding author
  • Zhang, Yu Shrike
  • Zhang, Weijia
Venue
Drug Discovery Today
Publisher
Elsevier BV
Published
2017-09
Volume
22
Issue
9
Pages
1392-1399
ISSN
1359-6446 (ISSN-L)
OpenAlex
W2604347510
Cited by
127
References
73
Citations by year
2026: 5 · 2025: 5 · 2024: 16 · 2023: 11 · 2022: 13 · 2021: 19 · 2020: 14 · 2019: 19 · 2018: 17 · 2017: 8
FWCI
1.27
Type
journal article
Language
en
Open access
Locations
  • Drug Discovery Today (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (K99CA201603)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
organ-on-a-chip, nanomedicine, tumor microenvironment, drug delivery, preclinical models, microfluidic model
MeSH terms
Animals, Humans, Models, Biological, Neoplasms, Biomimetic Materials, Nanomedicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review